511
Participants
Start Date
February 29, 2012
Primary Completion Date
August 31, 2013
Study Completion Date
August 31, 2013
Reslizumab
Reslizumab administered at a dosage of 3.0 mg/kg by intravenous (iv) infusion by qualified study personnel every 4 weeks for 16 weeks (for a total of 4 doses).
Placebo
Matching placebo administered by intravenous (iv) infusion by qualified study personnel every 4 weeks for 16 weeks (for a total of 4 doses).
Investigational Site 861, Birmingham
Investigational Site 842, Homewood
Investigational Site 887, Jasper
Investigational Site 809, Tucson
Investigational Site 892, Tucson
Investigational Site 846, Little Rock
Investigational Site 828, Anaheim
Investigational Site 900, Fresno
Investigational Site 862, Huntington Beach
Investigational Site 852, Los Angeles
Investigational Site 909, Los Angeles
Investigational Site 864, Newport Beach
Investigational Site 812, Rancho Mirage
Investigational Site 808, Riverside
Investigational Site 804, Sacramento
Investigational Site 837, Centennial
Investigational Site 851, Denver
Investigational Site 832, Wheat Ridge
Investigational Site 855, Jacksonville
Investigational Site 865, Miami
Investigational Site 881, Miami
Investigational Site 805, Albany
Investigational Site 870, Stockbridge
Investigational Site 816, Chicago
Investigational Site 824, Shiloh
Investigational Site 883, Evansville
Investigational Site 878, Fort Wayne
Investigational Site 820, Lenexa
Investigational Site 873, Owensboro
Investigational Site 801, Lafayette
Investigational Site 877, Mandeville
Investigational Site 875, White Marsh
Investigational Site 871, Fall River
Investigational Site 834, North Dartmouth
Investigational Site 889, Troy
Investigational Site 838, Rolla
Investigational Site 818, St Louis
Investigational Site 841, St Louis
Investigational Site 857, Albuquerque
Investigational Site 819, Newburgh
Investigational Site 844, Charlotte
Investigational Site 845, Middleburg Heights
Investigational Site 810, Tulsa
Investigational Site 859, Ashland
Investigational Site 859, Portland
Investigational Site 854, Jenkintown
Investigational Site 843, Providence
Investigational Site 802, Florence
Investigational Site 814, Orangeburg
Investigational Site 821, Spartanburg
Investigational Site 829, Spartanburg
Investigational Site 850, Knoxville
Investigational Site 803, Nashville
Investigational Site 880, Dallas
Investigational Site 858, Dickinson
Investigational Site 869, Live Oak
Investigational Site 879, Plano
Investigational Site 847, Salt Lake City
Investigational Site 876, West Jordan
Investigational Site 840, Fairfax
Investigational Site 836, Richmond
Investigational Site 867, Seattle
Investigational Site 833, Spokane
Investigational Site 904, Vancouver
Investigational Site 806, Greenfield
Investigational Site 823, La Crosse
Teva Branded Pharmaceutical Products R&D, Inc.
INDUSTRY